Antithrombotic treatment in atrial fibrillation. Response to: Bereznicki LR, Peterson GM, Jackson SL, Jeffrey EC: the risks of warfarin use in the elderly. Expert Opin. Drug Saf. (2006) 5(3):417-431.
Borja
Javier
J
García
Olga
O
Izquierdo
Iñaki
I
D000074:Acenocoumarol / Q000009:adverse effects; D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012459:Salicylates / Q000627:therapeutic use*; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors; D012459:Salicylates; C016167:triflusal; D014859:Warfarin; D000074:Acenocoumarol